Equity Profile

BMRN

BioMarin Pharmaceutical Inc.

Health CareBiotechnology$13.3B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.95

Revenue

Total revenue provides insight into the company's sales performance and market demand for its products.

$932M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. With a market cap of $13 billion, it plays a significant role in the health care sector, particularly in rare diseases and genetic disorders.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly below the estimate of $0.78, resulting in a 2.44% surprise. The stock reacted positively, gaining 2.59% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BioMarin to report an EPS of $0.95 and revenue of $932 million for Q2-2026. The market is watching closely for any signs of growth or challenges in their product pipeline.

Bull Case

If BioMarin exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies, leading to a positive market reaction.

Bear Case

Conversely, if the company misses on EPS or revenue, it may raise concerns about its growth prospects, potentially leading to a negative reaction from investors.

Key Metrics to Watch

EPS

$0.95

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$932M

Total revenue provides insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioMarin achieve an EPS of at least $0.95?

This figure is critical as it aligns with analyst expectations and indicates the company's profitability.

What is the revenue growth rate compared to the consensus of $932 million?

Revenue performance will signal market demand and the effectiveness of BioMarin's product offerings.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating BioMarin's ability to leverage its existing product portfolio for revenue growth, especially given recent positive trends in rare disease treatments.

Supporting Evidence

The company has a history of beating EPS estimates, with a 75% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders expect volatility which could be driven by positive surprises.

Key Risk

If the company reports revenue growth significantly above $932 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on whether BioMarin can meet or exceed expectations after a mixed performance in previous quarters.

Bull Confirmed If

An EPS of $1.05 or higher would confirm strong demand and profitability.

Bear Confirmed If

An EPS below $0.80 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could see a modest positive reaction, potentially around +2.59%.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors assess management commentary.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of around -0.37%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any changes in guidance regarding future revenue expectations.
3Insights into the competitive landscape for rare disease treatments.
4Management's commentary on operational efficiencies and cost management.
5Details on regulatory developments affecting product approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.95

Revenue

Total revenue provides insight into the company's sales performance and market demand for its products.

$932M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly below the estimate of $0.78, resulting in a 2.44% surprise. The stock reacted positively, gaining 2.59% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BioMarin to report an EPS of $0.95 and revenue of $932 million for Q2-2026. The market is watching closely for any signs of growth or challenges in their product pipeline.

Bull Case

If BioMarin exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies, leading to a positive market reaction.

Bear Case

Conversely, if the company misses on EPS or revenue, it may raise concerns about its growth prospects, potentially leading to a negative reaction from investors.

Key Metrics to Watch

EPS

$0.95

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$932M

Total revenue provides insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will BioMarin achieve an EPS of at least $0.95?

This figure is critical as it aligns with analyst expectations and indicates the company's profitability.

What is the revenue growth rate compared to the consensus of $932 million?

Revenue performance will signal market demand and the effectiveness of BioMarin's product offerings.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating BioMarin's ability to leverage its existing product portfolio for revenue growth, especially given recent positive trends in rare disease treatments.

Supporting Evidence

The company has a history of beating EPS estimates, with a 75% success rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders expect volatility which could be driven by positive surprises.

Key Risk

If the company reports revenue growth significantly above $932 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on whether BioMarin can meet or exceed expectations after a mixed performance in previous quarters.

Bull Confirmed If

An EPS of $1.05 or higher would confirm strong demand and profitability.

Bear Confirmed If

An EPS below $0.80 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could see a modest positive reaction, potentially around +2.59%.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors assess management commentary.

Miss

A miss on earnings could lead to a decline, with historical data suggesting an average drop of around -0.37%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any changes in guidance regarding future revenue expectations.
3Insights into the competitive landscape for rare disease treatments.
4Management's commentary on operational efficiencies and cost management.
5Details on regulatory developments affecting product approvals.